Overview of paclitaxel (TAXOL®) in advanced lung cancer

Research output: Contribution to journalArticle

Abstract

Paclitaxel (TAXOL®), a novel diterpene plant product isolated from the western yew Taxus brevifolia, is an active agent in the treatment of lung cancer. In two studies, the drug produced 21% and 24% objective response rates among patients with non-small cell lung cancer. A response rate of 34% was reported in a single trial involving patients with extensive-stage small cell lung cancer. Additional trials are needed to evaluate single-agent paclitaxel in the treatment of small cell lung cancer. Studies also are planned to measure the effect of paclitaxel as a radiosensitizer and in combination regimens with other active agents for the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)46-49
Number of pages4
JournalSeminars in Oncology
Volume20
Issue number4 SUPPL. 3
StatePublished - 1993

Fingerprint

Paclitaxel
Lung Neoplasms
Small Cell Lung Carcinoma
Taxus
Diterpenes
Non-Small Cell Lung Carcinoma
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Overview of paclitaxel (TAXOL®) in advanced lung cancer. / Ettinger, David S.

In: Seminars in Oncology, Vol. 20, No. 4 SUPPL. 3, 1993, p. 46-49.

Research output: Contribution to journalArticle

@article{b4ce710b25884613bbe77f718d984c2b,
title = "Overview of paclitaxel (TAXOL{\circledR}) in advanced lung cancer",
abstract = "Paclitaxel (TAXOL{\circledR}), a novel diterpene plant product isolated from the western yew Taxus brevifolia, is an active agent in the treatment of lung cancer. In two studies, the drug produced 21{\%} and 24{\%} objective response rates among patients with non-small cell lung cancer. A response rate of 34{\%} was reported in a single trial involving patients with extensive-stage small cell lung cancer. Additional trials are needed to evaluate single-agent paclitaxel in the treatment of small cell lung cancer. Studies also are planned to measure the effect of paclitaxel as a radiosensitizer and in combination regimens with other active agents for the treatment of lung cancer.",
author = "Ettinger, {David S}",
year = "1993",
language = "English (US)",
volume = "20",
pages = "46--49",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 3",

}

TY - JOUR

T1 - Overview of paclitaxel (TAXOL®) in advanced lung cancer

AU - Ettinger, David S

PY - 1993

Y1 - 1993

N2 - Paclitaxel (TAXOL®), a novel diterpene plant product isolated from the western yew Taxus brevifolia, is an active agent in the treatment of lung cancer. In two studies, the drug produced 21% and 24% objective response rates among patients with non-small cell lung cancer. A response rate of 34% was reported in a single trial involving patients with extensive-stage small cell lung cancer. Additional trials are needed to evaluate single-agent paclitaxel in the treatment of small cell lung cancer. Studies also are planned to measure the effect of paclitaxel as a radiosensitizer and in combination regimens with other active agents for the treatment of lung cancer.

AB - Paclitaxel (TAXOL®), a novel diterpene plant product isolated from the western yew Taxus brevifolia, is an active agent in the treatment of lung cancer. In two studies, the drug produced 21% and 24% objective response rates among patients with non-small cell lung cancer. A response rate of 34% was reported in a single trial involving patients with extensive-stage small cell lung cancer. Additional trials are needed to evaluate single-agent paclitaxel in the treatment of small cell lung cancer. Studies also are planned to measure the effect of paclitaxel as a radiosensitizer and in combination regimens with other active agents for the treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027220561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027220561&partnerID=8YFLogxK

M3 - Article

C2 - 8102017

AN - SCOPUS:0027220561

VL - 20

SP - 46

EP - 49

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 3

ER -